Story thread · 11 reports / 7 sources
FDA Committee Votes Down Duchenne Drug
medpagetoday.com · 12d
How the coverage leans
Across 7 sources · syndicated copies counted once
(MedPage Today) -- An FDA panel said that trial data did not provide substantial evidence showing that investigational deramiocel was effective in treating cardiomyopathy among patients with Duchenne muscular dystrophy. In a 9-3 vote, the FDA...
First report: FDA staff flags concerns about Capricor's Duchenne heart disease therapy — reuters.com, 15d
The coverage
- Capricor Duchenne cell therapy voted down by FDA panel
biopharmadive.com · 13d
- FDA, Capricor battle over DMD cell therapy's efficacy at adcomm
endpts.com · 13d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.